Remibrutinib - Misplaced Pages

Chemical compound Pharmaceutical compound

Remibrutinib
Clinical data

ATC code	L04AA60 (WHO)
Identifiers
IUPAC name N-ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide
CAS Number	1787294-07-8
PubChem CID	118107483
IUPHAR/BPS	10457
DrugBank	DB16852
ChemSpider	78317000
ChEMBL	ChEMBL4483575
PDB ligand	N6Z (PDBe, RCSB PDB)
Chemical and physical data
Formula	C₂₇H₂₇F₂N₅O₃
Molar mass	507.542 g·mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C
InChI InChI=1S/C27H27F2N5O3/c1-4-23(35)34(3)9-10-37-25-24(31-14-32-26(25)30)20-12-18(28)13-22(15(20)2)33-27(36)19-8-7-17(11-21(19)29)16-5-6-16/h4,7-8,11-14,16H,1,5-6,9-10H2,2-3H3,(H,33,36)(H2,30,31,32) Key:CUABMPOJOBCXJI-UHFFFAOYSA-N

Remibrutinib is a small molecule drug that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is in development for the treatment of chronic spontaneous urticaria. In November 2023, Novartis announced that the compound "demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo" in a Phase III trial.

References

Maurer, Marcus; Berger, William; Giménez-Arnau, Ana; Hayama, Koremasa; Jain, Vipul; Reich, Adam; Haemmerle, Sibylle; Lheritier, Karine; Walsh, Pauline; Xia, Summer; Storim, Julian (December 2022). "Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria". The Journal of Allergy and Clinical Immunology. 150 (6): 1498–1506.e2. doi:10.1016/j.jaci.2022.08.027. hdl:10230/55511. ISSN 1097-6825. PMID 36096203.
Maurer, Marcus; Giménez-Arnau, Ana; Jain, Vipul; Tillinghast, Jeffrey; Tolcachier, Alberto; Nigen, Simon; Hayam, Koremasa; Lheritier, Karine; Walsh, Pauline; Haemmerle, Sibylle (February 2022). "Remibrutinib Treatment Improves Quality of Life in Patients with Chronic Spontaneous Urticaria". Journal of Allergy and Clinical Immunology. 149 (2): AB179. doi:10.1016/j.jaci.2021.12.589. S2CID 246522006.
"Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2". Novartis. Retrieved 11 November 2023.